Core Insights - Dr. Adrian Bot has joined Immuthera's Board of Directors to enhance the company's pipeline development and commercialization efforts in cell therapies [2][4] - Immuthera is a subsidiary of PolTREG S.A., which specializes in innovative immune therapies focusing on regulatory T cell technologies [2][10] - Dr. Bot's extensive experience includes leadership roles in companies like Capstan Therapeutics and Kite Pharma, contributing to the development of significant CAR-T therapies [3][6] Company Overview - PolTREG is recognized as a global leader in developing T-regulatory cell products, with over 12 years of clinical experience involving more than 100 patients [5][10] - The company is advancing a range of products and technologies, including CAR-engineered Tregs and multi-edited, allogeneic CAR-Tregs, aimed at treating autoimmune diseases [5][10] - Immuthera is focused on pioneering novel cell-based therapies for clinical development in the U.S. and Canada, leveraging PolTREG's research and development capabilities [11] Leadership and Expertise - Dr. Bot brings 27 years of experience in the U.S. biopharmaceutical industry, with a strong focus on CAR-T cell products [6] - His previous roles include founding Chief Scientific Officer at Capstan Therapeutics, where he secured $165 million in financing and facilitated a $2.1 billion acquisition by AbbVie [4][6] - At Kite Pharma, Dr. Bot played a crucial role in the development of Yescarta® and Tecartus®, which were pivotal in the CAR-T therapy landscape [3][4] Strategic Initiatives - PolTREG is intensifying its presence in the American market, establishing a Scientific Advisory Board with key opinion leaders [9] - The company is collaborating with Kinexum Services LLC for FDA clinical, manufacturing, and regulatory strategy, and with Antion Biosciences for developing new CAR-Treg therapies [9] - PolTREG's lead product, PTG-007, is an autologous Treg treatment for early-onset Type-1 Diabetes, which is ready for Phase 2/3 clinical testing [10]